Advertisement
News
Advertisement

Alnylam to speed lead drug candidates' development

Sun, 02/12/2012 - 8:31am
Mass High Tech: The Journal of New England Technology

Alnylam Pharmaceuticals Inc. (Nasdaq: ALNY) of Cambridge said it will accelerate development of two lead drug candidates that offer the greatest commercial opportunity, and that it has discovered a novel method to monitor the activity of RNAi in blood samples and granted the first license to Isis Pharmaceuticals.

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading